Pfizer Inc.

26.38
0.19 (0.73%)
At close: Mar 21, 2025, 3:59 PM

Company Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.

In addition, the company is involved in the contract manufacturing business.

It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.

The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc.
Pfizer Inc. logo
Country United States
IPO Date Jun 1, 1972
Industry Drug Manufacturers - General
Sector Healthcare
Employees 81,000
CEO Dr. Albert Bourla D.V.M., Ph.D.

Contact Details

Address:
235 East 42nd Street
New York, New York
United States
Website https://www.pfizer.com

Stock Details

Ticker Symbol PFE
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000078003
CUSIP Number 717081103
ISIN Number US7170811035
Employer ID 13-5315170
SIC Code 2834

Key Executives

Name Position
Dr. Albert Bourla D.V.M., Ph.D. Chairman of the Board & Chief Executive Officer
David M. Denton Chief Financial Officer & Executive Vice President
Douglas M. Lankler Executive Vice President & Chief Legal Officer
Dr. Chris Boshoff FMedSci, M.D., Ph.D. Chief Scientific Officer and President of Research & Development
Dr. Michael S. Vincent M.D., Ph.D. Senior Vice President and Chief Scientific Officer of Inflammation & Immunology
Francesca M. DeMartino Chief Investor Relations Officer
Jennifer B. Damico Senior Vice President, Controller & Principal Accounting Officer
Lidia L. Fonseca Executive Vice President and Chief Digital & Technology Officer
Payal Sahni Becher Chief People Experience Officer & Executive Vice President
Sally M. Susman Executive Vice President & Chief Corporate Affairs Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 18, 2025 4 Filing
Mar 13, 2025 ARS Filing
Mar 13, 2025 DEFA14A Filing
Mar 13, 2025 DEF 14A Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing